Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of RS PHARMA is 4.2% (elevated). The 2023 annual accounts show equity of €43k and a net result of €38k. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 1 annual account.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Trust signals
3 signalsAdministrative Flags
0 eventsFinancials
Annual accounts & ratios
Source: NBB · 2023| Fiscal year | 2023 |
|---|---|
| Revenue | - |
| EBITDA | €50k |
| Net profit | €38k |
| Cash flow | €38k |
| Staff costs | - |
| Income taxes | €13k |
| Dividends | - |
| Total assets | €64k |
| Equity | €43k |
| Debt | €22k |
| of which ≤ 1y | €22k |
| of which > 1y | - |
| Working capital | €42k |
| Employees (FTE) | - |
| 2023 | |
|---|---|
| Current ratio | 2.92 |
| Quick ratio | 2.92 |
| Working capital ratio | 64.6% |
| Solvency | 66.4% |
| Debt / equity | 0.51 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | 58.6% |
| ROE | 88.3% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €64k |
| Fixed assets | 21/28 | €1k |
| Tangible fixed assets | 22/27 | €1k |
| Current assets | 29/58 | €63k |
| Amounts receivable within one year | 40/41 | €10k |
| Cash & bank | 54/58 | €53k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €64k |
| Equity | 10/15 | €43k |
| Contributions / capital | 10/11 | €5k |
| Accumulated profits (losses) | 14 | €38k |
| Amounts payable | 17/49 | €22k |
| Amounts payable within one year | 42/48 | €22k |
| Income statement | ||
| Gross operating margin | 9900 | €50k |
| Operating result | 9901 | €50k |
| Result before taxes | 9903 | €50k |
| Income taxes | 67/77 | €13k |
| Net result for the period | 9904 | €38k |
| Result to be appropriated | 9905 | €38k |
Health barometer
FY 2023 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Structure & network
Locations & real estate
Establishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21342B0045/00X003 | Brussels | 327 m² | 1 · 60 m² | 12.2 m · 3 fl. |
Analysis
Snowflake analysis
financial profile on 5 axesExceptional profile, strong across almost every axis.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector, ranked by comparable sizeCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameFR | RS PHARMA |